Navigation Links
Promus in Medical News

Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study

...da. Abbott also supplies a private-label version of XIENCE V to Boston Scientific called the PROMUS(R) Everolimus-Eluting Coronary Stent System. promus is designed and manufactured by Abbott and supplied to Boston Scientific as part of a distribution agreement between the two companies. Everolimu...

Boston Scientific Announces Schedule for EuroPCR 2009

...p.m. in Room 129. promus (R) Stent. Eberhard Grube, M.D., will present...c exhibit booth. TAXUS, Express, Express2 and promus are trademarks of Boston Scientific Corporation or its affiliates. The promus Stent is a private-labeled XIENCE V Everolimus-Elu...

Boston Scientific Announces Schedule For ACC 2009

... Sunday, March 29 promus (R) and TAXUS (R) Stents . During a poster ...ources. TAXUS, Express, Express2, Liberte and promus are trademarks of Boston Scientific Corporation or...rk of Abbott Laboratories group of companies. The promus Stent is a private-labeled XIENCE V Everolimus-Elu...

Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2008

...business Increased U.S. drug-eluting stent (DES) leadership with Q4 market share of 47 percent; exited the quarter with 49 percent (25 percent promus and 24 percent TAXUS(R) stent systems) Grew Neuromodulation sales 10 percent over prior year "During the quarter, we contin...

Abbott Begins U.S. Study of XIENCE V(TM) Drug Eluting Stent Designed for Small Vessels

...vices Agency. Abbott supplies a private-labeled XIENCE V to Boston Scientific called the PROMUS(TM) Everolimus-Eluting Coronary Stent System. promus is manufactured by Abbott and supplied to Boston Scientific as part of a distribution agreement between the two companies. Everolimus, develop...

Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter

...on Scientific's share of the market. Opening new promus accounts The Company announced it has: increased...ly to existing accounts, and has begun opening new promus accounts. The Company said it has ordered sufficient additional promus supply to continue opening new accounts through th...

Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System

...ach on a highly deliverable stent platform." The promus and XIENCE V stent systems are investigational devices in the U.S. and not yet approved for sale. promus is a private-labeled XIENCE V everolimus-eluting s... and distributed by Boston Scientific. TAXUS and promus are trademarks of Boston Scientific Corporation or...
Promus in Medical Technology

Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent

... approval for both the TAXUS Element Stent and the promus Element Stent Systems in the fourth quarter of thi...mated to be completed by the end of the year. The promus Element Stent System is currently being studied in...LATINUM clinical trial program, which compares the promus Element Stent System to the PROMUS(R) Stent System...

Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientific's TAXUS(R) Liberte(R) Stent

...ts with diabetes in December 2007. In the United States, the TAXUS Stents are not specifically indicated for use in patients with diabetes. The promus Stent is a private-labeled XIENCE V(R) Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific. XIENCE V...

Clinical Data Reinforce Safety and Efficacy of Boston Scientific's Two Drug- Eluting Stent Platforms

...roups, and included 892 patients randomized to the promus (XIENCE V) Stent and 410 patients treated with the...esults and some subgroups at two years favored the promus (XIENCE V) Stent for rates of Major Adverse Cardia... Medical Officer of Boston Scientific. "While the promus (XIENCE V) Stent performed well against the TAXUS ...

Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years

...y. Abbott also supplies a private-label version of XIENCE V to Boston Scientific called the PROMUS(R) Everolimus-Eluting Coronary Stent System. promus is designed and manufactured by Abbott and supplied to Boston Scientific as part of a distribution agreement between the two companies. Everolimu...

Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents

...g stents -- the TAXUS Element(TM) Paclitaxel-Eluting Coronary Stent and the promus Element Everolimus-Eluting Coronary Stent -- in Europe later this year. The TAXUS Liberte Atom, TAXUS Liberte Long, TAXUS Element and promus Element stents are investigational devices and are restricted under U.S. la...

Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent

...t 160 sites worldwide. The trial will compare the promus Element Everolimus-Eluting Coronary Stent to the P...strength, recoil and visibility. In addition, the promus Element Stent System incorporates the new Apex(TM)...alia. "The new alloy and stent design of the promus Element Stent promise to offer improved deliverabi...

Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent

...s Agency. Abbott also supplies a private-labeled XIENCE V to Boston Scientific called the PROMUS(TM) Everolimus-Eluting Coronary Stent System. promus is manufactured by Abbott and supplied to Boston Scientific as part of a distribution agreement between the two companies. Everolimus, develope...

SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents

...e are very pleased that both the TAXUS Express and promus Stents continue to perform so well in the SPIRIT I...growing body of positive clinical evidence for the promus Stent at two years," said Paul LaViolette, Chief O... drugs on two highly deliverable platforms." The promus Stent is a private-labeled XIENCE V Everolimus-Elu...

Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms

...tem ("TAXUS Stent") in 300 patients in Europe. The promus Stent is a private-labeled XIENCE V Everolimus-Elu...drugs on two deliverable platforms - the TAXUS and promus Stents. The results were presented today at the SC...ton Scientific's two DES platforms - the TAXUS and promus Stents - both performed extremely well in the SPIR...

Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures

... (TVR) at one year was also similar, with 6.1% for promus and 7.5% for TAXUS (p=0.41). The overall MACE (Ma...ston Scientific. "We look forward to launching the promus Stent in the U.S., which will complement our pacli...ring physicians a deliverable Olimus option." The promus Stent has CE Mark approval and is distributed in m...
Promus in Biological Technology

Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System

...clears the way for Boston Scientific to launch the promus Stent immediately in the U.S. The promus Stent expands Boston Scientific's drug-eluting ste... and everolimus) on separate DES platforms. "The promus Stent has shown outstanding deliverability, low la...

Boston Scientific Announces Schedule for ACC 2008

...ain CE Mark approval for both the XIENCE V and promus Stents. The promus Stent is a private-labeled XIENCE V Everolimus... clinical outcome data for Boston Scientific's promus Everolimus-Eluting Stent and compare them with...

Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents

...tent in patients in routine clinical practice. The promus Stent is a private-labeled XIENCE(TM) V Everolimus...y Abbott and distributed by Boston Scientific. The promus Stent is an investigational device in the United S...f the patients at each site, half will receive the promus Stent and half will receive either the Cypher or t...
Other Tags
(Date:7/12/2014)... The report, "Phthalic Anhydride and Derivatives (Plasticizers, Unsaturated Polyester ... – Trends & Forecast to 2018," defines and segments ... volume and value. The report also estimates the demand ... phthalic anhydride is projected to grow from an estimated ... with a CAGR of 5.24% from 2013 to 2018. ...
(Date:7/12/2014)... 12, 2014 The Security Analytics market ... to $3,376.6 million by 2019, at an expected CAGR ... The challenges to counter the increasing number of security ... outdated cyber defense systems in organizations are enormous. Vendors ... remodeling their existing architecture to develop better and more ...
(Date:7/12/2014)... increase in the summer as people gather around fire pits, ... vulnerable to these seasonal fire hazards: children. "Young children ... putting their hands on the side of cooking grills," Dr. ... University Medical Center in Maywood, Ill., said in a Loyola ... with fire, you get burned, is true -- you ...
(Date:7/12/2014)... As DePuy Pinnacle hip lawsuits ( ... Bernstein Liebhard LLP notes the publication of a new ... failure of metal-on-metal hip replacements. The research, which appears ... Bone & Joint Surgery, looked at 597 patients ... at least twelve months earlier. The blood metal ion ...
(Date:7/12/2014)... 2014 Doylestown Hospital recently conducted an ... men’s health questions. Paddock tackles topics including main ... women live longer than men, and testosterone replacement therapy, ... Simple featured on Doylestown Hospital’s website, Dr. Brad ... any age. If you notice pain, bulging, or asymmetry ...
Breaking Medicine News(10 mins):Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Burn Injuries More Common in Summer 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2
(Date:7/11/2014)... at the Department of Energy,s Oak Ridge National ... by R&D Magazine in recognition of the year,s ... the tremendous value of our National Labs," said ... at the National Labs continues to help our ... scientific and technological innovations necessary to remain globally ...
(Date:7/11/2014)... German . ... refraction of X-rays through a specimen instead of attenuation ... are often of much higher quality than those based ... Franz Pfeiffer are particularly interested in developing new approaches ... phase-contrast imaging. One main goal is to make this ...
(Date:7/11/2014)... other group members to reduce aggression and gain access ... for grooming activities shows a certain pattern across the ... journal Biology Letters . , Grooming between individuals ... ulterior motives. To be groomed has hygienic benefits and ... individual can provide access to infants, mating opportunities and ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4New simple setup for X-ray phase contrast 2Baboons groom early in the day to get benefits later 2
Other Contents